Galli-Galli Disease - Saudi Dermatology Board Study Guide

S

Synopsis

Galli-Galli disease (GGD) is a rare autosomal dominant genodermatosis that falls under the broader category of reticulate pigmented disorders of the skin. GGD is thought to be an allelic variant of Dowling-Degos disease (DDD), the latter a pigmentary disorder characterized by progressive hyperpigmentation of flexural skin.

                    Distinguishing Feature: The distinguishing feature of GGD is the presence of suprabasal acantholysis histologically, and as such it has also been described as "acantholytic Dowling-Degos disease" in the literature.
                

Historical Context: In 1982, Bardach et al described the first cases of disease occurring in two brothers named Galli. The brothers presented with a reticulated hyperpigmented eruption affecting the skin folds. Biopsy demonstrated proliferation of rete ridges and basal layer hyperpigmentation as seen in DDD, but also focal suprabasal acantholysis.

Initially, GGD was favored to be a distinct clinical entity from DDD due to the unique and consistent feature of acantholysis; however, subsequent research supports a common etiology for DDD and GGD, as both have been found to share the same genetic defect.

🧬 Genetic Mechanism

Frameshift or nonsense KRT5 gene mutations lead to haploinsufficiency of keratin 5, a protein that plays an important role in:

• Cell-cell adhesion
• Epidermal differentiation
• Melanosome uptake

The mechanism by which specific KRT5 mutations seen in DDD and GGD cause skin disease or correlate with variable histological subtypes is not yet elucidated.

👁

Look For

Primary Clinical Features:

Reticulated hyperpigmentation in the flexural areas, including:

Neck Axilla Inframammary Inguinal regions

Lesions are often pruritic.

Initial Presentation: Initial presentation may include a papular, papulosquamous, or papulovesicular eruption, which precedes pigmentary changes.

Age at presentation ranges widely from teenage years up to the seventh decade of life

Disease is progressive without spontaneous remission. No Remission

🔄 Variant Manifestations

DDD-like features: Comedo-like lesions and pitted perioral scars typically seen in DDD
Grover-like presentations: Erythematous, keratotic papules concentrated on the trunk
Lentigo-like variant: Lentigo-like macules with pruritic erythematous papules of the trunk and extremities

💎

Diagnostic Pearls

🧬 Inheritance may be autosomal dominant or sporadic. Ask about family members with a similar condition.

🔬 Histological Hallmark

The hallmark histological finding of focal suprabasal acantholysis separates GGD from other reticulate pigmented disorders of the skin.

🔍

Differential Diagnosis & Pitfalls

To perform a comparison, select diagnoses from the classic differential

Other reticulate pigmented disorders of the skin may be difficult to distinguish clinically, but the finding of suprabasal acantholysis on biopsy is exclusive to GGD.

🔹 Dowling-Degos disease (DDD)

GGD is an acantholytic variant of DDD. Clinically, DDD may show comedo-like lesions and pitted perioral acneiform scars not typically seen in GGD.

🔹 Reticulate acropigmentation of Kitamura

Presents with acral hyperpigmented atrophic macules / pits or palmar fissures.

🔹 Reticulate acropigmentation of Dohi (dyschromatosis symmetrica hereditaria)

Presents with acral hyper- and hypopigmented macules on the dorsal hands and feet.

🔹 Haber syndrome

Verruciform papular lesions of trunk and roseate facial erythema, often presenting in childhood.

🔹 Darier disease

Earlier onset, seborrheic distribution, characterized by crusted yellow-brown papules rather than lentigo-like macules; nail changes and mucous membrane involvement. On biopsy, dyskeratosis seen in Darier disease and not GGD.

🔹 Hailey-Hailey disease

Erosions in skin folds, dilapidated brick wall histology.

🔹 Grover disease

Very pruritic keratotic papules on trunk; acantholysis and dyskeratosis seen on biopsy, no elongation of rete ridges as in GGD.

🔹 Epidermolysis bullosa with mottled pigmentation

Also caused by keratin 5 mutation; has additional features of palmoplantar hyperkeratosis, bullous lesions.

🔹 Pemphigus vulgaris

Cutaneous and mucosal involvement, plus Nikolsky, plus immunofluorescence.

🔹 Confluent and reticulated papillomatosis

(Gougerot-Carteaud syndrome)

🔹 Granular parakeratosis

🔹 Acanthosis nigricans

🧪

Best Tests

🔬 Skin Biopsy - Primary Diagnostic Tool

Skin biopsy is useful in differentiating GGD from other reticulate pigmented disorders of the skin. Histopathological examination of lesional skin will show:

Elongation of the rete ridges and basal layer hyperpigmentation as seen in DDD
Hallmark feature: pronounced focal suprabasal acantholysis

Immunofluorescence: Immunofluorescence studies should also be performed to rule out an unusual variant of pemphigus vulgaris.

🧬 Genetic Testing

Larger academic centers may offer genetic testing for specific keratin 5 frameshift mutations observed in some, but not all, patients with GGD.

Important: Genetic testing is not necessary for diagnosis, but may be helpful for clinically challenging cases.

⚕️

Management Pearls

Galli-Galli disease can be autosomal dominant or sporadic. As such, genetics referral may be considered to discuss the implications of this inheritance pattern for the patient and family members.

Extracutaneous Manifestations: There are no known extracutaneous manifestations of GGD which would compel additional workup.

⚠️ Malignancy Surveillance

An increased incidence of squamous cell carcinomas and keratoacanthomas has been reported in patients with DDD. This association has not yet been described in the small number of cases of GGD; however, as GGD is a variant of DDD, regular screening skin examinations would be prudent for these patients.

💊

Therapy

⚠️ Treatment Reality

There is no best treatment for GGD. Case reports of attempted therapies include:

Topical steroids
Topical retinoids
UVB phototherapy

Result: All without significant improvement.

✅ Success Case Report

There is a single case report of a patient successfully treated with erbium:YAG laser resulting in remittance of lesions through the follow-up interval of 12 months.